I am responsible for identifying, evaluating, making and managing equity investments aligned with the future directions of Pfizer. My focus will be on early stage biotechnology companies that are developing new therapeutics to treat diseases in Oncology, Neuroscience, Inflammation and Immunology, Internal Medicine and Rare Diseases.

• Built a team of synthetic chemists focused on new technologies to accelerate the discovery and development of new molecules from the mg to kg scale from Lead Development to First in Human clinical studies. • Built six new groups focused on biocatalysis, photo-redox, flow, reaction optimization, parallel medicinal chemistry and DNA encoded libraries. Integrated these technologies into synthetic management team strategies. As a result, these technologies have enabled numerous teams to advance more rapidly and the impact coupled with Early Process Enablement spend has been acceleration by 2 months at up to 25% cost reduction.• Designed the strategy to build Pfizer’s proprietary DNA encoded library for screening against new targets. • Leader of the Joint Steering Committee for both the HitGen and TSRI collaborations. At the end of 2017, 5 libraries with over 2 billion compounds were prepared and 3 of the 5 TSRI proposal advanced to attempting the novel chemical reactions on DNA.• Built the strategy to invest our Science and Technology budget.

• Built the strategy and executed the tactics of the Antibody Drug Conjugate medicinal chemistry group, Natural Products group and devised the strategy around targeted nanoparticles to deliver novel immune-oncology drugs. Delivered 5 clinical candidates using our most innovative technologies. Specifically, the site specific conjugates for the NG Her2, CDCP1 and EDB program and developed the novel DNA damaging linker payload in the CPI dimer series for the CD33 and CD123 programs. • In addition, maintained all of the associated responsibilities of my Senior Director role below.My group focused on the discovery of novel cytotoxins, linkers and site specific conjugation methods for the discovery of ADCs for the treatment of cancer. The group's primary skill sets include: medicinal chemistry design, synthetic chemistry, natural products discovery, computational chemistry, microbiology and analytical chemistry.

• Developed the strategy and designed the organizational structure and developed a new medicinal chemistry group to delivery novel payloads, linkers and antibody drug conjugates for the treatment of cancer. • 6 conjugates were advanced to clinical trial (5T4, Notch3, Trop2, EFNA4a, PTK7, GD3), 4 using proprietary payloads and site-specific linker technology developed by my team, for which I am an co-inventor of these products. • Member of Oncology Leadership team managing a portfolio of over 20 small molecule and ADC programs. • Co-Leader of the ADC Strategy Team. Responsible for building networks with Oncology Research Unit located in Pearl River, NY and La Jolla, CA, Global Biotherapeutics Technologies group in Cambridge, MA, Rinat in San Francisco, CA, CovX in La Jolla, CA and Pharmaceutical Sciences groups located in Groton, CT and Pearl River, NY. • Developed key partnerships with Centers for Therapeutic Innovation (CTI) in Cambridge, MA, New York, NY and San Francisco, CA. • Chemistry point of contact for evaluating business development opportunities with outside partners. Established 4 key partners with the Oncology Research Unit (ORU) (Seattle Genetics, StemCentrx, Cytomx, Philogen). Additionally, reviewed and supported the Pfizer Venture Capital investment in Mersana.• Developed and chaired the Groton Synthesis Leadership Team to align the new Synthesis Team directors from the various research units and to work as a team to address all synthetic chemistry related management responsibilities. • Chair of the Groton medicinal chemistry safety team. Partnered with EH&S to develop standardized site practices for handling OEB5 compounds and Global Operations to build new infrastructure to handle fermentation and isolation laboratories. Managed a group of 6 PI’s including design, synthesis, computational and natural products medicinal chemists and their associated groups and external vendors.

• Developed the strategy and managed a portfolio of projects targeting Schizophrenia, Alzheimer’s Disease, Bipolar Disorder and Autism. During my leadership, 3 programs advanced from the exploratory stage to lead development (LLRK, CK1, PDE4), 2 programs identified clinical candidates (GSI, GSM) and 1 program advance to FIH (PDE2). Co-inventor of the GSI and GSM clinical candidate. • Responsible for organizational design and talent selection related to the Wyeth merge. Responsible for project assessment of the Wyeth portfolio and transfer of two clinical assets and 2 preclinical projects into our portfolio. • Led AB/CNS Medicinal Chemistry’s efforts to focus on improving our synthetic talent, recruiting new talent, creating new synthesis roles as well as new design roles especially around data analysis/chemoinformatics improvements for design excellence, education of medicinal chemistry staff, and the external communication strategy for our department. Additionally, led efforts to train our research project leaders to more effectively perform in their role. • As a member of the Neuroscience (NS) Portfolio Management Team, responsible for the strategic management and resource decisions for the NS portfolio (~20 programs ranging from exploratory to clinical candidate selection). Managed a group of up to 10 PI’s with a total group size of ~40 internal chemists and 15 external chemists.

• Drove the medicinal chemistry design and synthesis strategy for a portfolio of projects targeting diseases such as Schizophrenia (AMPA), Alzheimer’s Disease (GSM), Bipolar Disorder (CK1) and Autism (NRI/5HT1a). Three programs advanced from exploratory to lead development stage and four have resulted in the identification of clinical candidates, two are currently in Ph I/II clinical studies. • Led the Groton chemistry group’s efforts toward improving excellence in synthesis which resulted in dramatically improved infrastructure, education of our staff, communication of results and higher quality data sets. • As a member of the Neuroscience Portfolio Management Team, responsible for the strategic management and resource decisions for the NS portfolio (~20 programs ranging from exploratory to clinical candidate selection). Responsible for managing 6 PI laboratories and a group of 30 internal and 15 external chemists. Responsible for designing Synthesis only laboratories to help focus team on enabling the most desirable and challenging chemistry space. • Responsible for talent evaluation and project transition to the Groton Site upon the Ann Arbor site closure and for the transition of 3 PIs from Ann Arbor to the successful start up of group in Groton.

• Responsible for managing a group of 3 PhD laboratories along with my own laboratory. Each laboratory unit consisted of 1 PhD chemist and 2 MS/BS chemists. Total group size was 12 internal FTEs and 7 external FTEs. • Drove three projects for the treatment of Depression (SRI+), ADHD (H3) and Schizophrenia (AMPA). Two clinical candidates emerged from these efforts that were discovered in my laboratory (AMPA & SRI+). • Also served as the discovery team rep on the ADHD development team which drove multiple compounds toward clinical POC. • As a member of the CNS Portfolio Management Team, managed a portfolio of 15 projects for the CNS group.

Led a muti-disciplinary team (Chemistry, Biology, PDM, Safety ~ 30 FTEs) targeting novel programs for the treatment of depression. Our team’s efforts resulted in identification of 4 clinical candidates.

CNS Medicinal Chemistry, Pfizer Inc., Groton CT• Design and synthesis of biologically active compounds for the treatment of neurological disorders. • Inventor of four clinical candidates that advanced to human clinical trials (SRI+ - 3 candidates), 7 nAChR agonists).• Supervised 2 research associates, one summer intern and 4 outsourcing FTE’s. • Steering Committee Member and Chemical Working Group Leader for the ChemBridge File Enrichment collaboration.

CNS Medicinal Chemistry, Pfizer Inc., Groton CT• Design and synthesis of biologically active compounds for the treatment of neurological disorders. • Supervised 2 research associates, one summer intern and 3 outsourcing FTE’s. • Contributed to the discovery of two clinical candidates (GABAa and the 42 nAChR backup to varenicline). • Chemical Working Group Leader for the file enrichment collaboration with ChemBridge.

CNS Medicinal Chemistry, Pfizer Inc, Groton, CT • Design and synthesis of biologically active compounds for the treatment of neurological disorders. Supervised 2 research associates. • Inventor of the alpha 7 nAChR agonist clinical candidate, CP-810,123).